DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Insulin Delivery Devices Market by Type (Insulin Pens (Reusable, Disposable), Insulin Pumps (External/Tethered, Patch), Pen Needles (Standard, Safety), Insulin Syringes) and End User (Patients/Homecare, Hospitals & Clinics) - Global Forecast to 2021" report to their offering.
The insulin delivery devices market is projected to reach USD 17.85 billion by 2021 from USD 11.54 billion in 2016, growing at a CAGR of 9.1% in the next five years (2016 to 2021).
Favorable reimbursement scenario and strong government support in selected countries, technological advancements in insulin delivery devices, growing diabetic population, and rising awareness about insulin delivery devices are the major factors driving the growth of this market. However, needle anxiety, emergence of oral drug delivery methods, and the growing trend of reuse of pen needles and infusion sets are the major factors restraining the growth of this market.
Furthermore, increasing research and development activities and increasing diabetes-related health expenditure in emerging countries are likely to offer significant growth opportunities for players operating in the market.
- Growing Diabetic Population
- Technological Advancements in Insulin Delivery Devices
- Favorable Reimbursement Environment and Government Support in Selected Countries
- Conferences, Meetings, and Congresses to Create Awareness About Insulin Delivery Devices
- Poor Reimbursement Structure in Developing Countries
- Needle Anxiety in Patients to Affect the Growth of the Pen Needles and Syringes Market
- Oral Insulin as an Alternative Drug Delivery Method
- Issues Associated With the Reuse of Pen Needles and Infusion Sets
- Increasing Research and Development Activities
- Increasing Diabetes-Related Health Expenditure in Emerging Economies
- Safety Needles
- Severe Shortage of Endocrinologists in the U.S.
- Animas Corporation (Johnson and Johnson)
- Becton, Dickinson and Company
- Biocon Limited
- ELI Lilly and Company
- Insulet Corporation
- Medtronic PLC
- Novo Nordisk A/S
- Tandem Diabetes Care, Inc.
- Ypsomed Holding AG
For more information about this report visit http://www.researchandmarkets.com/research/bfp2pf/insulin_delivery